Comparison Overview

RRD Biopharma Development, a Uniphar Company

VS

Agilent Technologies

RRD Biopharma Development, a Uniphar Company

700 King Farm Blvd, Rockville, Maryland, 20850, US
Last Update: 2025-05-04 (UTC)
Between 800 and 900

Strong

RRD Biopharma Development is a drug development company with an alternative approach to achieving human-proof-of-concept (hPOC) that is intensely focused on minimizing time, risk, and cost while maximizing efficiency and probability of success. RRDโ€™s Product Development Team (PDT) model is ideal for companies interested in an asset-centric capital approach that can accelerate an hPOC value inflection as efficiently as possible while enabling the development of high-quality, pharmaceutical-grade data packages required by regulators and potential biopharma partners. The PDT model provides our partners with a โ€œplug and playโ€, high-caliber, and highly experienced drug development team that can be deployed immediately. Time and resources are not needlessly spent assembling the right development team or enduring consultant hand-offs on the front end, which can absorb 18 months or more, with no guarantee of coalescence, while impacting exclusivity and revenue on the back end. Paying for this learning curve is expensive. Together with our partners, we tailor strategies designed to optimize product value to a defined stage of development and then direct and manage execution of that strategy towards optimizing outcomes. Learn more about us at www.rrdbiodev.com

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 86
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Agilent Technologies

5301 Stevens Creek Boulevard, Santa Clara, CA, 95051, US
Last Update: 2025-05-06 (UTC)

Excellent

Between 900 and 1000

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilentโ€™s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilentโ€™s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 17,078
Subsidiaries: 11
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/rrd-international-llc.jpeg
RRD Biopharma Development, a Uniphar Company
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/agilent-technologies.jpeg
Agilent Technologies
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
Compliance Summary
RRD Biopharma Development, a Uniphar Company
100%
Compliance Rate
0/4 Standards Verified
Agilent Technologies
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for RRD Biopharma Development, a Uniphar Company in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Agilent Technologies in 2025.

Incident History โ€” RRD Biopharma Development, a Uniphar Company (X = Date, Y = Severity)

RRD Biopharma Development, a Uniphar Company cyber incidents detection timeline including parent company and subsidiaries

Incident History โ€” Agilent Technologies (X = Date, Y = Severity)

Agilent Technologies cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/rrd-international-llc.jpeg
RRD Biopharma Development, a Uniphar Company
Incidents

No Incident

https://images.rankiteo.com/companyimages/agilent-technologies.jpeg
Agilent Technologies
Incidents

No Incident

FAQ

Agilent Technologies company company demonstrates a stronger AI risk posture compared to RRD Biopharma Development, a Uniphar Company company company, reflecting its advanced AI governance and monitoring frameworks.

Historically, Agilent Technologies company has disclosed a higher number of cyber incidents compared to RRD Biopharma Development, a Uniphar Company company.

In the current year, Agilent Technologies company and RRD Biopharma Development, a Uniphar Company company have not reported any cyber incidents.

Neither Agilent Technologies company nor RRD Biopharma Development, a Uniphar Company company has reported experiencing a ransomware attack publicly.

Neither Agilent Technologies company nor RRD Biopharma Development, a Uniphar Company company has reported experiencing a data breach publicly.

Neither Agilent Technologies company nor RRD Biopharma Development, a Uniphar Company company has reported experiencing targeted cyberattacks publicly.

Neither RRD Biopharma Development, a Uniphar Company company nor Agilent Technologies company has reported experiencing or disclosing vulnerabilities publicly.

Agilent Technologies company has more subsidiaries worldwide compared to RRD Biopharma Development, a Uniphar Company company.

Agilent Technologies company employs more people globally than RRD Biopharma Development, a Uniphar Company company, reflecting its scale as a Biotechnology Research.

Latest Global CVEs (Not Company-Specific)

Description

An issue was discovered in chinabugotech hutool before 5.8.4 allowing attackers to execute arbitrary expressions that lead to arbitrary method invocation and potentially remote code execution (RCE) via the QLExpressEngine class.

Description

A weakness has been identified in JeecgBoot up to 3.8.2. The impacted element is an unknown function of the file /sys/role/exportXls. This manipulation causes improper authorization. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be exploited. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 4.0
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:N/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in JeecgBoot up to 3.8.2. The affected element is an unknown function of the file /sys/user/exportXls of the component Filter Handler. The manipulation results in improper authorization. The attack may be performed from remote. The exploit has been released to the public and may be exploited. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 4.0
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:N/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was identified in JeecgBoot up to 3.8.2. Impacted is an unknown function of the file /sys/tenant/deleteBatch. The manipulation of the argument ids leads to improper authorization. The attack is possible to be carried out remotely. The complexity of an attack is rather high. The exploitability is considered difficult. The exploit is publicly available and might be used. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 2.1
Severity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 2.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was determined in JeecgBoot up to 3.8.2. This issue affects some unknown processing of the file /api/getDepartUserList. Executing manipulation of the argument departId can lead to improper authorization. The attack can be executed remotely. This attack is characterized by high complexity. The exploitability is assessed as difficult. The exploit has been publicly disclosed and may be utilized. The vendor was contacted early about this disclosure but did not respond in any way.

Risk Information
cvss2
Base: 2.1
Severity: HIGH
AV:N/AC:H/Au:S/C:P/I:N/A:N
cvss3
Base: 3.1
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:U/C:L/I:N/A:N
cvss4
Base: 2.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:L/VI:N/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X